Ser654

Site Information
EPNMLLEsEDELLVD SwissProt Entrez-Gene
Blast this site against: NCBI SwissProt PDB
Site Group ID: 4270237

In vivo Characterization
Methods used to characterize site in vivo:	mass spectrometry ( 1 , 2 , 3 , 4 )
Disease tissue studied:	cervical cancer ( 2 ) , cervical adenocarcinoma ( 2 ) , leukemia ( 3 , 4 ) , chronic myelogenous leukemia ( 3 )
Relevant cell line - cell type - tissue:	HeLa S3 (cervical) ( 2 ) , K562 (erythroid) ( 3 ) , liver ( 1 )

Upstream Regulation
Treatments:	nocodazole ( 2 )

References
1	Bian Y, et al. (2014) An enzyme assisted RP-RPLC approach for in-depth analysis of human liver phosphoproteome. J Proteomics 96, 253-62 24275569 Curated Info
2	Olsen JV, et al. (2010) Quantitative phosphoproteomics reveals widespread full phosphorylation site occupancy during mitosis. Sci Signal 3, ra3 20068231 Curated Info
3	Stokes M (2008) CST Curation Set: 4394; Year: 2008; Biosample/Treatment: cell line, K562/untreated; Disease: chronic myelogenous leukemia; SILAC: -; Specificities of Antibodies Used to Purify Peptides prior to LCMS: p[STY]) Curated Info
4	Gu T (2007) CST Curation Set: 3304; Year: 2007; Biosample/Treatment: tissue, blood/untreated; Disease: leukemia; SILAC: -; Specificities of Antibodies Used to Purify Peptides prior to LCMS: pY Antibodies Used to Purify Peptides prior to LCMS: Phospho-Tyrosine Mouse mAb (P-Tyr-100) Cat#: 9411, PTMScan(R) Phospho-Tyr Motif (Y*) Immunoaffinity Beads Cat#: 1991 Curated Info